Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen tEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
1,478
Period ended Dec 31, 2025
Change on a year earlier
+52.1%
972 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,478 | +52.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 972 | +71.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 567 | +233.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 170 | – | Form 10-K (filed 2025-02-14) ↗ |
Breakdown
What makes up tezspire (tezepelumab-ekko — severe asthma) — worldwide product sales ($m)
- TEZSPIRE (tezepelumab-ekko — Severe Asthma) — U.S. product sales ($M)1,478 · FY2025
- TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Rest of World (ROW) product sales ($M)0 · FY2025
- TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%)52.0% · FY2025
- TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide volume growth YoY (%)–
Cite this data
StockData. (2026). Amgen TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_tezspire_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.